GlassScriptPhysician profile
Ashley P Hyder
NPI 1962416008
$843.06
in general payments reported to CMS, 2019-2025
23 companies · $141 in 2025
The $141 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $189 · 2020: $11.87 · 2021: $79.28 · 2022: $23.83 · 2023: $266 · 2024: $132 · 2025: $141.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $539.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $538.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $156.66 | 2021-2024 | |
| Lilly USA, LLC | $68.02 | 2023-2025 | Jardiance, Kisunla |
| Amgen INC. | $61.67 | 2019-2020 | |
| Exact Sciences Corporation | $60.75 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Abbott Laboratories | $57.51 | 2023-2024 | Freestyle Libre 3 |
| Astellas Pharma US INC | $48.55 | 2019-2023 | Veozah |
| Collegium Pharmaceutical, INC. | $45.20 | 2019 | |
| Glaxosmithkline, LLC. | $42.56 | 2025 | Shingrix, Arexvy, Bexsero |
| Madrigal Pharmaceuticals | $38.50 | 2025 | Rezdiffra |
| Medtronic, INC. | $37.34 | 2023 | Osteocool Rf Ablation System |
| Novo Nordisk INC | $31.28 | 2023-2024 | Wegovy, Rybelsus, Ozempic |
| Globus Medical, INC. | $23.83 | 2022 | |
| Janssen Pharmaceuticals, INC | $18.62 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $17.88 | 2021 | |
| Pfizer INC. | $16.83 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $16.20 | 2024 | Airsupra |
| Merck Sharp & Dohme LLC | $15.95 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $15.65 | 2023 | Camzyos |
| Janssen Biotech, INC. | $15.23 | 2019 | |
| Dexcom, INC. | $14.33 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.75 | 2019 | |
| Boston Scientific Corporation | $13.47 | 2021 | |
| Abiomed | $13.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Hyder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.